Page last updated: 2024-11-12
xyloketal a
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
xyloketal A: from mangrove fungus Xylaria sp. from the south China sea coast; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
xyloketal A : A xyloketal with formula C27H36O6. It was initially isolated from the mangrove fungus Xylaria sp. from the South China sea coast. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 10994129 |
| CHEMBL ID | 1171852 |
| CHEBI ID | 195288 |
| MeSH ID | M0403420 |
Synonyms (7)
| Synonym |
|---|
| CHEMBL1171852 |
| (-)-xyloketal a |
| (3r,3ar,5ar,8r,8ar,10ar,13r,13ar,15ar)-3,5a,8,10a,13,15a-hexamethyl-2,3,3a,7,8,8a,9,12,13,13a,14,15a-dodecahydro-4h,5ah,10ah-furo[2,3-b]bisfuro[3',2':5,6]pyrano[2,3-f:2',3'-h]chromene |
| (3r,3ar,5ar,8r,8ar,10ar,13r,13ar,15ar)-3,5a,8,10a,13,15a-hexamethyl-2,3,3a,7,8,8a,9,12,13,13a,14,15a-dodecahydro-4h,5ah,10ah-trifuro[3,2-e:3,2-e':3,2-e'']benzo[1,6-b:3,2-b':5,4-b'']tripyran |
| xyloketal a |
| CHEBI:195288 |
| (4r,7r,8r,13r,16r,17r,22r,25r,26r)-4,7,13,16,22,25-hexamethyl-3,5,12,14,21,23-hexaoxaheptacyclo[18.7.0.02,10.04,8.011,19.013,17.022,26]heptacosa-1,10,19-triene |
Research Excerpts
Overview
Xyloketal A is a ketal compound with a C(3) symmetry. XylokETals B-E are its analogues.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Xyloketal A is a ketal compound with a C(3) symmetry and xyloketals B-E are its analogues." | ( Five unique compounds: xyloketals from mangrove fungus Xylaria sp. from the South China Sea coast. Feng, S; Jiang, G; Jones, EB; Krohn, K; Lin, Y; Luo, J; Steingröver, K; Vrijmoed, LL; Wu, X; Zhou, S; Zsila, F, 2001) | 1.03 |
Actions
| Excerpt | Reference | Relevance |
|---|---|---|
| "Xyloketal A-D can inhibit AChE as well as BuChE activity in vitro. " | ( [Effects of metabolites of mangrove fungus Xylaria sp. from South China Sea Coast on the activity of acetylcholinesterase in vitro]. Jinghui, L; Xiongyu, W; Yingbao, Y; Yongcheng, L; Zhiliang, C, 2004) | 1.77 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Roles (1)
| Role | Description |
|---|---|
| EC 3.1.1.7 (acetylcholinesterase) inhibitor | An EC 3.1.1.* (carboxylic ester hydrolase) inhibitor that interferes with the action of enzyme acetylcholinesterase (EC 3.1.1.7), which helps breaking down of acetylcholine into choline and acetic acid. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Drug Classes (2)
| Class | Description |
|---|---|
| xyloketal | A group of natural compounds isolated from the marine mangrove fungus Xylaria sp. 2508 that have multiple pharmacological and therapeutic properties. |
| organic heteroheptacyclic compound | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Bioassays (6)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID492792 | Vasorelaxant activity in Sprague-Dawley rat endothelium denuded thoracic aortic rings assessed as inhibition of KCL-induced contraction | 2010 | Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12 | Design and synthesis of novel xyloketal derivatives and their vasorelaxing activities in rat thoracic aorta and angiogenic activities in zebrafish angiogenesis screen. |
| AID492795 | Induction of nitric oxide production in HUVEC at 20 uM after 24 hrs by griess reaction in presence of L-NAME | 2010 | Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12 | Design and synthesis of novel xyloketal derivatives and their vasorelaxing activities in rat thoracic aorta and angiogenic activities in zebrafish angiogenesis screen. |
| AID492791 | Vasorelaxant activity in Sprague-Dawley rat endothelium intact thoracic aortic rings assessed as inhibition of KPSS-induced contraction | 2010 | Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12 | Design and synthesis of novel xyloketal derivatives and their vasorelaxing activities in rat thoracic aorta and angiogenic activities in zebrafish angiogenesis screen. |
| AID492797 | Antiangiogenic activity in zebrafish embryo at 100 uM after 72 hrs by microscopical analysis | 2010 | Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12 | Design and synthesis of novel xyloketal derivatives and their vasorelaxing activities in rat thoracic aorta and angiogenic activities in zebrafish angiogenesis screen. |
| AID492794 | Induction of nitric oxide production in HUVEC at 20 uM after 24 hrs by griess reaction | 2010 | Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12 | Design and synthesis of novel xyloketal derivatives and their vasorelaxing activities in rat thoracic aorta and angiogenic activities in zebrafish angiogenesis screen. |
| AID492796 | Cytotoxicity against HUVEC assessed as cell viability > 200 uM after 24 hrs by MTT assay | 2010 | Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12 | Design and synthesis of novel xyloketal derivatives and their vasorelaxing activities in rat thoracic aorta and angiogenic activities in zebrafish angiogenesis screen. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.19
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.19) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||